| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000035941 |
| Receipt No. | R000040929 |
| Scientific Title | FFR guided DecISion making in COronary reVascularization: Japanese multi-cEnteR retrospective RegistrY |
| Date of disclosure of the study information | 2019/02/20 |
| Last modified on | 2022/08/04 (Ver. 7) |
| Basic information | ||
| Public title | FFR guided DecISion making in COronary reVascularization: Japanese multi-cEnteR retrospective RegistrY | |
| Acronym | FFR DISCOVERY Japan | |
| Scientific Title | FFR guided DecISion making in COronary reVascularization: Japanese multi-cEnteR retrospective RegistrY | |
| Scientific Title:Acronym | FFR DISCOVERY Japan | |
| Region |
|
|
| Condition | ||
| Condition | Coronary artery disease | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | 1) To elucidate the prognosis of patients after fractional flow reserve assessments
2) To clarify the optimal cut-off value of FFR for coronary revascularization on the basis of clinical outcomes |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | time to event for cardiac death, myocardial infarction, and target lesion revascularization |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients who underwent fractional flow reserve assessment in one or more coronary arteries | |||
| Key exclusion criteria | 1) Infarct related artery
2) Bypass graft 3) Thrombolysis in myocardial infarction flow (TIMI) <3 4) Overt heart failure 5) Severe valvular disease or cardiomyopathy (Hypertrophic, dilated, or restrictive cardiomyopathy) 6) Limited life expectancy (less than 12 months) 7) If patients or their family elect to opt out of study participation |
|||
| Target sample size | 5000 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Wakayama Medical University | ||||||
| Division name | Department of cardiovascular medicine | ||||||
| Zip code | 641-8510 | ||||||
| Address | 811-1 Kimiidera Wakayama Japan | ||||||
| TEL | 073-447-2300 | ||||||
| akasat@wakayama-med.acj.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Wakayama Medical University | ||||||
| Division name | Department of cardiovascular medicine | ||||||
| Zip code | 641-8510 | ||||||
| Address | 811-1 Kimiidera Wakayama Japan | ||||||
| TEL | 073-447-2300 | ||||||
| Homepage URL | |||||||
| yshiono@wakayama-med.ac.jp | |||||||
| Sponsor | |
| Institute | Wakayama Medical University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Japan Heart Foundation |
| Organization | |
| Division | |
| Category of Funding Organization | Non profit foundation |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Wakayama Medical University |
| Address | 811-1 Kimiidera Wakayama Japan |
| Tel | 073-447-2300 |
| wa-rinri@wakayama-med.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 和歌山県立医科大学 (和歌山県)
東京医科大学 (東京都) 東京医科大学八王子医療センター (東京都) 岐阜ハートセンター (岐阜県) 京都第二赤十字病院 (京都府) 愛知医科大学 (愛知県) 江戸川病院 (東京都) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | NA |
| Publication of results | Unpublished |
| Result | |||||||
| URL related to results and publications | NA | ||||||
| Number of participants that the trial has enrolled | 5007 | ||||||
| Results | A total of 5004 patients who underwent FFR measurement between 2010 and 2016 were enrolled and were followed until March 2020.
Of those, 2886 patients underwent revascularization after FFR measurements. During the follow up, 87 patients suffered from cardiac death and 59 patients suffered non-fatal myocardial infarction. |
||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results | |||||||
| Baseline Characteristics | Among the patients enrolled in this study, 3728 (74.5%) were men, the average age was 69.7, 3783(75.6%) had chronic coronary syndrome, 659 (13.2%) had prior myocardial infarction, 421 (8.4%) had unstable angina, 118 (2.4%) had ST-segment elevated myocardial infarction, and 23 (0.5%) had non-ST-segment elevated myocardial infarction. 4026 (80.5) patients had hypertension, 3354 (67%) had dyslipidemia, 2098 (41.9%) had diabetes mellitus, 1268 (25.3%) had prior myocardial infarction, 462 (9.2%) had chronic kidney disease, 340 were on hemodyalysis, 541 (10.8%) had peripheral artery disease, 499 (10.0%) had prior stroke, and 384 (7.7%) had atrial fibrillation. | ||||||
| Participant flow | Between January 2010 and December 2016, 5007 patients who underwent FFR evaluation were screened, 2 did not meet the inclusion criteria, and 1 met the exclusion criteria. In the end, 50004 patients were enrolled and were followed until March 2020. | ||||||
| Adverse events | No adverse event related to this study was observed due to the nature of the retrospective study. | ||||||
| Outcome measures | During the follow up, 87 patients suffered from cardiac death and 59 patients suffered non-fatal myocardial infarction. The cumulative incidence of cardiac death was 0.44% at 1 year, 1.27% at 3 year, and 2.3% at 5 year. With regard to non-fatal myocardial infarction, the cumulative incidence was 0.27% at 1 year, 0.8% at 3 year, and 1.54% at 5 year. | ||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | Retrospective cohort study |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040929 |